The aim of this study was to identify a chemotherapy combination that would be active and well tolerated for palliative treatment of advanced non-small-cell lung cancer (NSCLC). From February 1992 to December 1994, a total of 77 patients affected by stage-IIIB and stage-IV NSCLC were treated with carboplatin 350 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8 of each cycle, with cycles repeated every 28 days. All patients were evaluable for response and toxicity. A total of 24 patients showed a partial response (31% response rate; 95% CI = 21-41%). The median duration of overall survival was 41 weeks (95% CI = 31-51), and the median time to disease progression was 34 weeks (95% CI = 25-43). The treatment was well tolerated: no grade-4 toxicity was observed. The carboplatin-vinorelbine combination deserves to considered as a valid alternative to regiments that include cisplatin for palliative treatment of advanced NSCLC.
From the Department of Pneumology (C.S., R.R.), Azienda Ospedaliera Careggi, Florence; Department of Radiotherapy (E.T., F.P., A.B.), Azienda Ospedaliera Senese, Siena; Medical Oncology Service (M.R., P.G.), Azienda U.S.L. 8, Arezzo; and Department of Medicine (R.A., A.A.), Azienda U.S.L. 9, Grosseto, Italy.
Address correspondence and reprint requests to Dr. Enrico Tucci, Department of Radiotherapy, Policlinico Le Scotte, 53100 Siena, Italy.